First Time Loading...

Moderna Inc
NASDAQ:MRNA

Watchlist Manager
Moderna Inc Logo
Moderna Inc
NASDAQ:MRNA
Watchlist
Price: 106.56 USD -3.64%
Updated: Mar 29, 2024

Intrinsic Value

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). [ Read More ]

The intrinsic value of one MRNA stock under the Base Case scenario is 33.43 USD. Compared to the current market price of 106.56 USD, Moderna Inc is Overvalued by 69%.

Key Points:
MRNA Intrinsic Value
Base Case
33.43 USD
Overvaluation 69%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Moderna Inc

Backtest MRNA Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling MRNA stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

How can I assist you today?

Provide an overview
of Moderna Inc's business.

What risks and challenges
does Moderna Inc face in the near future?

Summarize the latest earnings report
of Moderna Inc.

Provide P/E
for Moderna Inc and its competitors.

Financials

Balance Sheet Decomposition
Moderna Inc

Current Assets 10.3B
Cash & Short-Term Investments 8.6B
Receivables 1.1B
Other Current Assets 640m
Non-Current Assets 8.1B
Long-Term Investments 4.7B
PP&E 2.7B
Intangibles 96m
Other Non-Current Assets 604m
Current Liabilities 3B
Accounts Payable 520m
Accrued Liabilities 1.8B
Other Current Liabilities 672m
Non-Current Liabilities 1.6B
Long-Term Debt 575m
Other Non-Current Liabilities 982m
Efficiency

Earnings Waterfall
Moderna Inc

Revenue
6.8B USD
Cost of Revenue
-4.7B USD
Gross Profit
2.2B USD
Operating Expenses
-6.4B USD
Operating Income
-4.2B USD
Other Expenses
-475m USD
Net Income
-4.7B USD

Free Cash Flow Analysis
Moderna Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

MRNA Profitability Score
Profitability Due Diligence

Moderna Inc's profitability score is 73/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Exceptional 3-Year Average ROIC
Negative Free Cash Flow
Exceptional 3-Years Revenue Growth
73/100
Profitability
Score

Moderna Inc's profitability score is 73/100. The higher the profitability score, the more profitable the company is.

MRNA Solvency Score
Solvency Due Diligence

Moderna Inc's solvency score is 74/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Long-Term Solvency
Negative Net Debt
Low D/E
74/100
Solvency
Score

Moderna Inc's solvency score is 74/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

MRNA Price Targets Summary
Moderna Inc

Wall Street analysts forecast MRNA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MRNA is 131.93 USD with a low forecast of 61.61 USD and a high forecast of 325.5 USD.

Lowest
Price Target
61.61 USD
42% Downside
Average
Price Target
131.93 USD
24% Upside
Highest
Price Target
325.5 USD
205% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

MRNA Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

MRNA Price
Moderna Inc

1M 1M
+16%
6M 6M
+3%
1Y 1Y
-28%
3Y 3Y
-14%
5Y 5Y
+424%
10Y 10Y
+473%
Annual Price Range
106.56
52w Low
69.51
52w High
160.53
Price Metrics
Average Annual Return 140.51%
Standard Deviation of Annual Returns 234.65%
Max Drawdown -86%
Shares Statistics
Market Capitalization 40.7B USD
Shares Outstanding 382 072 992
Percentage of Shares Shorted 7.69%

MRNA Return Decomposition
Main factors of price return

What is price return decomposition?

MRNA News

Other Videos

Last Important Events
Moderna Inc

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Moderna Inc

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Moderna Inc Logo
Moderna Inc

Country

United States of America

Industry

Biotechnology

Market Cap

40.7B USD

Dividend Yield

0%

Description

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Cambridge, Massachusetts and currently employs 2,700 full-time employees. The company went IPO on 2018-12-07. The Company’s mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range of spectrum of diseases. The company is developing vaccines and therapeutics for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with its strategic collaborators. The firm develops technologies that enable the development of mRNA medicines for diverse applications. The company has created modalities, including prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, and systemic intracellular therapeutics. The firm develops technologies that enable the development of mRNA medicines.

Contact

MASSACHUSETTS
Cambridge
200 Technology Sq
+16177146500.0
https://www.modernatx.com/

IPO

2018-12-07

Employees

2 700

Officers

CEO & Director
Mr. Stephane Bancel
Chief Financial Officer
Mr. James M. Mock

See Also

Discover More
What is the Intrinsic Value of one MRNA stock?

The intrinsic value of one MRNA stock under the Base Case scenario is 33.43 USD.

Is MRNA stock undervalued or overvalued?

Compared to the current market price of 106.56 USD, Moderna Inc is Overvalued by 69%.